About Sinopharm
Sinopharm is a Healthcare company based in Beijing (China) founded in 2009 by Mahmoud Aziz and Lee Leonardo, and was acquired by Nuance Pharma in January 2022. Vaccines for infectious diseases including EV71 and COVID-19 are developed. The company has 7 employees. Its chief executive, as recorded, is Mahmoud Aziz. Its website sinopharm.com draws about 52 thousand monthly visits. Its Indian entity Sinopharm India Private Limited reported revenue of ₹1.82 Cr. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.
Company details
Established in 2009 in Beijing, China, focus is placed on biotechnology and pharmaceuticals, particularly vaccines targeting infectious diseases. The primary product, an inactivated EV71 vaccine, addresses hand, foot, and mouth disease in children. Research and development are conducted for polio, COVID-19, and pneumonia vaccines. Additional lines encompass in vitro diagnostic kits, medical consumables, protective materials, and smart wearable devices.
- Headquarters Beijing, China
- Employees 7
- Founders Mahmoud Aziz, Lee Leonardo
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website sinopharm.com
- Social LinkedIn
- Acquired by Nuance Pharma (Jan 2022)
- Legal Name Sinopharm India Private Limited
- Date of Incorporation 10 Dec, 2012
- Jurisdiction New Delhi, Delhi, India
- Indian entity revenue₹1.82 Cr
FY 2024 · -66% YoY
- Indian entity net loss-₹47.6 Lakh
FY 2024 · -26% margin
- Indian entity EBITDA-₹47.5 Lakh
FY 2024 · -26% margin
- Investors
- Employee Count7
- Acquired byNuance Pharma
(Jan 2022)
Associated legal entities of Sinopharm
Sinopharm operates through Sinopharm India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sinopharm India Private Limited CIN U51397DL2012FTC245919 | Active | 10 Dec 2012 | New Delhi, Delhi | ₹1.8 Cr | 7 | 2 | View details |
Funding Insights of Sinopharm
- Total Rounds 1
All 1 funding rounds of Sinopharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Sinopharm
Sinopharm has secured backing from 1 investor. Prominent investors backing the company include Nuance Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of drugs for anemia and respiratory diseases | 2014 | nuancepharma.com | Shanghai, China |
Investor details for Sinopharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sinopharm India Private Limited (Sinopharm)
Sinopharm India Private Limited is the primary company behind Sinopharm. The board of Sinopharm India Private Limited currently have 2 directors; the longest-serving is Liao Chuankun, appointed in 2012. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Liao Chuankun DIN 06437498 | Director | 10 Dec 2012 | 13 yrs 10 mo | Sinopharm India Private Limited |
| Rajesh Singh Rathore DIN 09132411 | Director | 06 Apr 2021 | 5 yrs 6 mo | Sinopharm India Private Limited |
People of Sinopharm
24 people are tracked at Sinopharm (8 in leadership, 15 in board & advisors, 1 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Mahmoud Aziz | Co-Founder & CEO | Leadership |
Lee Leonardo | Co-Founder | Leadership |
Liu Yong | Executive Director, President | Leadership |
Cai Maisong | Vice President | Leadership |
Li Yang | Vice President | Leadership |
Jiang Xiuchang | Vice President | Leadership |
Li Xiaojuan | CFO | Leadership |
Chen Zhanyu | Vice President | Leadership |
Li Zhiming | Executive Director, Chairman | Board & advisors |
Wu Tak Lung | Independent Non-executive Director | Board & advisors |
Chen Fangruo | Independent non-executive Director | Board & advisors |
Wen Deyong | Non-Executive Director | Board & advisors |
Ma Ping | Non-Executive Director | Board & advisors |
Deng Jindong | Non-Executive Director | Board & advisors |
Zhuo Fumin | Independent Non-Executive Director | Board & advisors |
Li Peiyu | Independent non-executive Director | Board & advisors |
Chen Qiyu | Non-Executive Director & Vice Chairman | Board & advisors |
Feng Rongli | Non-Executive Director | Board & advisors |
Hu Jianwei | Non-Executive Director | Board & advisors |
Li Dongjiu | Non-Executive Director | Board & advisors |
4 more people are available in the full profile.
Complete people profiles for Sinopharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Sinopharm
Figures of Sinopharm India Private Limited, the primary company behind Sinopharm, for FY 2024. Revenue was ₹1.82 Cr (-66% year on year). Net loss was -₹47.6 Lakh (-26% margin). EBITDA was -₹47.5 Lakh (-26% margin). Revenue has grown at a compounded annual rate of -54% over three years and -44% over five years.
- ₹1.82 CrRevenue · FY 2024 · -66% YoY
- -₹47.6 LakhNet loss · -26% margin
- -₹47.5 LakhEBITDA · -26% margin
- ₹4.80 CrPaid-up capital
- 7Employees (provident fund records)
- -54%Revenue CAGR, 3 years
- -44%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Sinopharm India Private Limited are on its company page.
Detailed financial statements for Sinopharm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Sinopharm
4 dated milestones of Sinopharm across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Sinopharm is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Exit Acquired by Nuance Pharma.
Web traffic of Sinopharm
The website of Sinopharm (sinopharm.com) receives about 51.6K visits a month and ranks #492,192 among all websites worldwide, #481 in Biotechnology and Pharmaceuticals.
- Monthly visits51.6K
▲ 12.7% vs previous month
- Unique visitors16K
per month
- Global rank#492,192
among all websites
- Category rank#481
Health · Biotechnology and Pharmaceuticals
- Bounce rate28%
- Pages per visit6.2
- Average visit3 min 27 sec
- DevicesDesktop 86% · Mobile 14%
Websites whose visitors overlap most with Sinopharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cncm.com.cn | 100% | View details | |||
| sinopharmholding.com | 89% | 117.2K | #231,349 | View details | |
1jiankang.com | 1jiankang.com | 52% | – | ||
cms.herbalgram.org | cms.herbalgram.org | 51% | – | ||
cnphars.org | cnphars.org | 51% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Sinopharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sinopharm
Complete news archive for Sinopharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sinopharm
Sinopharm was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Sinopharm is headquartered in Beijing, China.
Mahmoud Aziz is the CEO of Sinopharm, as recorded in our data. They have also founded this company.
Sinopharm has 7 employees.
The primary company behind Sinopharm, Sinopharm India Private Limited, reported revenue of ₹1.82 Cr for FY 2024, down 66% year on year.
Established in 2009 in Beijing, China, focus is placed on biotechnology and pharmaceuticals, particularly vaccines targeting infectious diseases. The primary product, an inactivated EV71 vaccine, addresses hand, foot, and mouth disease in children. Research and development are conducted for polio, COVID-19, and pneumonia vaccines. Additional lines encompass in vitro diagnostic kits, medical consumables, protective materials, and smart wearable devices.
Sinopharm has 1 investor. Key investors include Nuance Pharma.
Sinopharm operates through Sinopharm India Private Limited.
Yes. Sinopharm was acquired by Nuance Pharma in January 2022.
The legal entities of Sinopharm currently have 2 directors, including Rajesh Singh Rathore, Liao Chuankun.